Literature DB >> 17040626

Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein.

Katherine Stemke-Hale1, Bryan Hennessy, Gordon B Mills, Rahul Mitra.   

Abstract

The completion of the human genome project, along with the ancillary technologies derived from this effort, provides the ability to comprehensively analyze patient tumors as well as the individual patient's own genetic make-up at the DNA, RNA, and protein level. As a result, novel molecular screening techniques have the potential to push the boundaries of detection to even smaller tumors and also to allow accurate risk assessment, cancer prevention, and treatment planning in individual women. This review focuses on advances over the past 2 years in the use of molecular signatures and circulating tumor cells for early breast cancer detection and for prediction of response to therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17040626     DOI: 10.1007/s11912-006-0078-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  68 in total

1.  Familial breast cancer screening: ethical and social implications.

Authors:  A Paradiso; F Muggia
Journal:  Ann Oncol       Date:  2004       Impact factor: 32.976

Review 2.  Breast cancer susceptibility and the DNA damage response.

Authors:  Vesna Dapic; Marcelo A Carvalho; Alvaro N A Monteiro
Journal:  Cancer Control       Date:  2005-04       Impact factor: 3.302

Review 3.  From signatures to models: understanding cancer using microarrays.

Authors:  Eran Segal; Nir Friedman; Naftali Kaminski; Aviv Regev; Daphne Koller
Journal:  Nat Genet       Date:  2005-06       Impact factor: 38.330

Review 4.  SERMs in chemoprevention of breast cancer.

Authors:  Milena Gasco; Alessandra Argusti; Bernardo Bonanni; Andrea Decensi
Journal:  Eur J Cancer       Date:  2005-09       Impact factor: 9.162

5.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.

Authors:  Raoul Tibes; Yihua Qiu; Yiling Lu; Bryan Hennessy; Michael Andreeff; Gordon B Mills; Steven M Kornblau
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

6.  Separation of human breast cancer cells from blood by differential dielectric affinity.

Authors:  F F Becker; X B Wang; Y Huang; R Pethig; J Vykoukal; P R Gascoyne
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

7.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

Review 8.  Immunotherapy and cancer vaccines in the management of breast cancer.

Authors:  Georg Sauer; Christian Kurzeder; Volker Heilmann; Rolf Kreienberg; Helmut Deissler
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

9.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

10.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

View more
  5 in total

Review 1.  Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives.

Authors:  Stephen G Grant; Melissa A Melan; Jean J Latimer; Paula A Witt-Enderby
Journal:  Expert Rev Mol Med       Date:  2009-02-05       Impact factor: 5.600

2.  MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer.

Authors:  Lina Gu; Meixiang Sang; Danjing Yin; Fei Liu; Yunyan Wu; Shina Liu; Weina Huang; Baoen Shan
Journal:  Thorac Cancer       Date:  2018-02-12       Impact factor: 3.500

Review 3.  Nanotechnology Advances in the Detection and Treatment of Cancer: An Overview.

Authors:  Sareh Mosleh-Shirazi; Milad Abbasi; Mohammad Reza Moaddeli; Ahmad Vaez; Mostafa Shafiee; Seyed Reza Kasaee; Ali Mohammad Amani; Saeid Hatam
Journal:  Nanotheranostics       Date:  2022-08-21

Review 4.  Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome.

Authors:  Ferdinando Mannello; Daniela Ligi
Journal:  BMC Cancer       Date:  2013-07-12       Impact factor: 4.430

5.  Clinical implications and utility of field cancerization.

Authors:  Gabriel D Dakubo; John P Jakupciak; Mark A Birch-Machin; Ryan L Parr
Journal:  Cancer Cell Int       Date:  2007-03-15       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.